Finding 384773 (2023-003)

Significant Deficiency
Requirement
B
Questioned Costs
$1
Year
2023
Accepted
2024-03-26
Audit: 297887
Organization: Legacy Medical Care Inc. (IL)

AI Summary

  • Core Issue: Incorrect calculation of indirect costs using the 10% de minimis rate led to potential unallowable costs.
  • Impacted Requirements: Costs must be consistently charged as either indirect or direct, with no double charging.
  • Recommended Follow-Up: Management should review monthly calculations of indirect costs to ensure accuracy.

Finding Text

Federal Agency: U.S. Department of Health and Human Services Federal Program Name: COVID-19 Vaccines Community-Based Education & Outreach (IVAX) Assistance Listing Number: 93.268 Pass-Through Entity: Illinois Primary Health Care Association Pass-Through Number: N/A Award Periods: July 1, 2022 – March 31, 2023 Type of Finding: Immaterial Noncompliance and Significant deficiency in internal control over compliance Criteria: A non-Federal entity that does not have a current negotiated indirect cost rate, may elect to charge a de minimis rate of 10% of modified total direct costs (MTDC) which may be used indefinitely. No documentation is required to justify the 10% de minimis indirect cost rate. As described in § 200.403, costs must be consistently charged as either indirect or direct costs, but may not be double charged or inconsistently charged as both. If chosen, this methodology once elected must be used consistently for all Federal awards until such time as a non-Federal entity chooses to negotiate for a rate, which the non-Federal entity may apply to do at any time. Condition: Legacy incorrectly calculated the reimbursement of in-direct costs when using the de minimis rate of 10%. Questioned Costs: $3,404. Context: Three (3) of three (3) in-direct cost transactions selected for testing. Cause: Unknown. Effect: Calculating indirect costs incorrectly could result in unallowable costs being charged to the grant. Repeat Finding: No. Recommendation: We recommend that a member of management review the monthly calculation of indirect costs to ensure it is calculated correctly. Views of Responsible Officials: There is no disagreement with the audit finding.

Corrective Action Plan

Action taken in response to finding: • All costs charged to grants will be reviewed and verified. • Indirect costs will be checked and verified for all grants

Categories

Questioned Costs Allowable Costs / Cost Principles Subrecipient Monitoring

Other Findings in this Audit

  • 384770 2023-002
    Significant Deficiency
  • 384771 2023-005
    Material Weakness Repeat
  • 384772 2023-006
    Significant Deficiency Repeat
  • 384774 2023-004
    Significant Deficiency Repeat
  • 961212 2023-002
    Significant Deficiency
  • 961213 2023-005
    Material Weakness Repeat
  • 961214 2023-006
    Significant Deficiency Repeat
  • 961215 2023-003
    Significant Deficiency
  • 961216 2023-004
    Significant Deficiency Repeat

Programs in Audit

ALN Program Name Expenditures
93.268 Immunization Cooperative Agreements $210,112
93.323 Epidemiology and Laboratory Capacity for Infectious Diseases (elc) $82,636
93.527 Affordable Care Act (aca) Grants for New and Expanded Services Under the Health Center Program $64,146
93.332 Cooperative Agreement to Support Navigators in Federally-Facilitated and State Partnership Marketplaces $34,711